Navigation Links
Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
Date:10/29/2007

developed CPG 52364 to inhibit these TLRs more effectively. In Coley's preclinical studies, CPG 52364 showed a marked increase in therapeutic potency compared to HCQ, preventing the development of anti-DNA antibodies in SLE-prone mice, while also exhibiting an improved safety profile.

In addition to its activity as a monotherapy, preclinical data showed that the combination of CPG 52364 with HCQ delivers added efficacy, suggesting that CPG 52364 could be used clinically either in combination with HCQ or as a replacement therapy for HCQ in the first-line treatment of SLE.

Coley plans to present data from its preclinical research with CPG 52364 at The 71st annual meeting of the American College of Rheumatology (ACR) at the new Boston Convention and Exhibition Center in Boston, Massachusetts. Dr. Arthur Krieg, Coley's Executive Vice President of Research and Development and Chief Scientific Officer will deliver a presentation on Friday, November 9, 2007 at 2:45pm EST, entitled, "Antimalarials are More Effective at Inhibiting Toll-Like Receptor 9 than at Inhibiting Antigen Presentation" (Presentation #1310).

Dr. Grayson Lipford, Vice President, Basic Research for Coley Pharmaceutical Group, plans to present a poster entitled, "Selective Toll-like Receptor 7/8/9 Antagonists for the Oral Treatment of Autoimmune Diseases," (Poster Board #210). The poster will be available for viewing on Saturday, November 10, 2007 from 8:00am to 4:30pm EST.

About Systemic Lupus Erythematosus (SLE)(1)

SLE is a chronic autoimmune disease that affects nearly 500,000 Americans. The disease, which is nine times more prevalent in women than men, and is also more prevalent in minorities, occurs when the immune system produces antibodies that cause inflammation, pain and damage to various tissues and organs in the body.

SLE is a leading cause of kidney disease, stroke, and premature cardiovascular disease in women of childbearing age. There is no known cure for
'/>"/>

SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/18/2013)... (May 18, 2013) There are significant cost ... used to diagnose or treat gastrointestinal problems, according ... , A study by New York Presbyterian ... objective testing may substantially reduce the cost and ... GERD is believed to affect nearly 25 percent ...
(Date:5/18/2013)... Today, Zane Benefits, Inc. published ... in Marketplaces . Zane Benefits, which provides comprehensive ... benefits, is the leader in health care reform, ... arrangements . , According to Zane Benefits’ website, ... recently released a much-anticipated statement and Q&A on ...
(Date:5/18/2013)... 2013 After working diligently for months and ... formally announced the integration of the fitment specs for the ... set to stun the automobile market with its extraordinary features ... is marked as the latest entry in the size ... up for the year 2013. , Aptly suiting its ...
(Date:5/18/2013)... Although obesity is associated with an increased risk ... esophageal adenocarcinoma, a type of esophageal cancer, is stronger ... on Cancer.gov, last reviewed in January 2012, overweight ... those of normal and healthy weight to develop this ... cancer is not well understood, it is now thought ...
(Date:5/18/2013)... Houston, TX (PRWEB) May 18, 2013 Show ... many years of various different training systems that is all ... possible has caught the attention of http://ShowAndGoTrainingReview.com ’s ... Go Training is a unique “four phase system” designed ... the minimum amount of time spent working out in the ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... polymer, fitted with molecular pincers of carefully tailored structure, ... can be used for fabrication of sensitive and selective ... the near future also in gases. Moreover, the polymer ... for therapeutic purposes. The collaboration of researchers of ...
... tripled in the United States between 1999 and 2006, ... heroin overdoses combined. Hospitalizations and emergency room visits related ... name Oxycontin) and hydrocodone (Vicodin) also increased dramatically in ... the August issue of Health Affairs describes ...
... Goodwin HealthDay Reporter , WEDNESDAY, Aug. 3 ... certain markers in the blood called "autoantibodies" is showing ... blood test correctly detected Alzheimer,s disease in people already ... accuracy, according to the researchers. The test could also ...
... Society of America (GSA) the nation,s largest interdisciplinary organization ... Ferraro, PhD, of Purdue University as the 2011 recipient of ... given to individuals who have not only fostered excellence in ... of their mentoring, and whose inspiration is sought by students ...
... A Mayo Clinic orthopedic surgeon suspects that the nagging ... knees may be different from what men encounter, and ... study to explore the question. The Society for Women,s ... (ISIS) Network on Musculoskeletal Health has awarded a group ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) and five other ... to identify a new potential treatment for acute myeloid leukemia ... 3, the scientists have pinpointed a protein called Brd4 as ... that is currently incurable in 70% of patients. Using a ...
Cached Medicine News:Health News:Polymer's hunt for nicotine 2Health News:Polymer's hunt for nicotine 3Health News:Group Health establishes major initiative to prevent opioid abuse and overdose 2Health News:Group Health establishes major initiative to prevent opioid abuse and overdose 3Health News:Another Blood Test for Alzheimer's Shows Promise 2Health News:Another Blood Test for Alzheimer's Shows Promise 3Health News:Another Blood Test for Alzheimer's Shows Promise 4Health News:Ferraro to receive GSA's 2011 Distinguished Mentorship in Gerontology Award 2Health News:Mayo Clinic examines why knee osteoarthritis afflicts more women than men 2Health News:Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia 2Health News:Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia 3Health News:Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia 4
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: